Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study

BACKGROUND AND AIMS: Glecaprevir/pibrentasvir (GLE/PIB) has shown high efficacy and safety in chronic HCV‐infected adults and adolescents; data in children were limited. DORA part 2 is a phase 2/3, nonrandomized, open‐label study evaluating the pharmacokinetics, efficacy, and safety of a pediatric f...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonas, Maureen M., Rhee, Susan, Kelly, Deirdre A., Del Valle‐Segarra, Antonio, Feiterna‐Sperling, Cornelia, Gilmour, Susan, Gonzalez‐Peralta, Regino P., Hierro, Loreto, Leung, Daniel H., Ling, Simon C., Lobzin, Yuri, Lobritto, Steven, Mizuochi, Tatsuki, Narkewicz, Michael R., Sabharwal, Vishakha, Wen, Jessica, Kei Lon, Hoi, Marcinak, John, Topp, Andrew, Tripathi, Rakesh, Sokal, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548879/
https://www.ncbi.nlm.nih.gov/pubmed/33811356
http://dx.doi.org/10.1002/hep.31841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548879/
https://www.ncbi.nlm.nih.gov/pubmed/33811356
http://dx.doi.org/10.1002/hep.31841

Ejemplares similares